4-nitro-N-(4-(trifluoromethyl)phenyl)benzamide | 7607-41-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-nitro-N-(4-(trifluoromethyl)phenyl)benzamide
• 英文别名: 4-nitro-N-(4-trifluoromethylphenyl)benzamide；N-(4-trifluoromethylphenyl)-4-nitrobenzamide；4-nitro-benzoic acid-(4-trifluoromethyl-anilide)；4-Nitro-benzoesaeure-(4-trifluormethyl-anilid)；4-nitro-N-[4-(trifluoromethyl)phenyl]benzamide
• CAS: 7607-41-2
• 化学式: C₁₄H₉F₃N₂O₃
• 分子量: 310.232
• InChiKey: GGUCEKQVOWOZNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-nitro-N-(4-(trifluoromethyl)phenyl)benzamide 在 铁粉 、 氯化铵 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 C₂₀H₂₂F₃N₃O₂
  参考文献：
  名称：

  发现含有脲部分的苯甲酰胺衍生物作为可溶性环氧化物水解酶抑制剂

  摘要：

  通过抑制可溶性环氧化物水解酶 (sEH) 提高环氧脂肪酸可有效治疗炎症和疼痛相关疾病。在此，我们报道了一系列含有尿素部分的苯甲酰胺衍生物作为 sEH 抑制剂的发现。密集的结构修饰导致化合物A34被鉴定为具有良好物理化学性质的有效 sEH 抑制剂。分子对接揭示了独特的酰胺支架和 Phe497 之间的额外氢键相互作用，有助于增强 sEH 抑制效力。化合物A34对人 sEH 表现出出色的抑制活性，IC 50值为 0.04 ± 0.01 nM，K i值为 0.2 ± 0.1 nM。它还在体内代谢研究中显示出适度的全身药物暴露和口服生物利用度。在角叉菜胶诱导的炎性疼痛大鼠模型中，与t -AUCB和塞来昔布相比，化合物A34表现出更好的治疗效果。体内代谢研究和炎症性疼痛评估表明，A34可能是开发高效 sEH 抑制剂的可行先导化合物。

  DOI：

  10.1016/j.bioorg.2022.105898
• 作为产物：
  描述：

  对硝基苯甲酸 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 4-nitro-N-(4-(trifluoromethyl)phenyl)benzamide
  参考文献：
  名称：

  1,4-二氢苯并[1,2,4]三嗪基自由基的衍生物中的官能团转化

  摘要：

  官能团的转化OCOPh，OCH 2 PH，I，NO 2和CO 2我在布拉特的自由基衍生物1 - 5是在为了开发合成工具苯并掺入[1,2,4]三嗪基系统成复杂的调查分子结构。因此，OCOPh的碱性水解或PCH催化的OCH 2 Ph的脱苄基作用使苯酚官能度被酰化和烷基化。Pd催化的碘衍生物1c，1d和2d的Suzuki，Negishi，Sonogashira和Heck C-C交叉偶联反应也是成功和有效的。NO的还原2在1E生成苯胺衍生物1t，将其用己醛还原烷基化并偶联至l-脯氨酸。通过EPR和电子吸收光谱对选定的苯并[1,2,4]三嗪基进行了表征，并通过DFT计算方法对结果进行了分析。最后，使用B3LYP / 6-31G（2d，p）方法研究了1,4-二氢苯并[1,2,4]三嗪环的形成机理。

  DOI：

  10.1021/jo500898e

文献信息

• SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF
  申请人：Wang Jeh-Jeng

  公开号：US20120215154A1

  公开（公告）日：2012-08-23

  The present invention provides a method of preparing a compound of formula 6 comprising: (a) reacting a compound of formula 1 with a compound of formula 2 to form a compound of formula 3 wherein X of formula 2 is Cl or OH; (b) treating the compound formula 3 with Lawesson's reagent to form a compound of formula 4 (c) reacting a compound of formula 4 with potassium ferricyanide to produce a compound of formula 5 and (d) performing catalytic reduction of nitro group of the compound of formula 5 with palladium on charcoal to generate the compound of formula 6, wherein R 1 of formulae 1-6 is H, C 1-10 alkyl, C 1-10 alkoxy or C 1-10 haloalkyl, and R 2 of formulae 1-6 is H or C 1-10 alkyl. The present invention also provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R 1 and R 2 are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue; wherein growth of the tumor is inhibited.

  本发明提供了一种制备6式化合物的方法，包括：(a) 将1式化合物与2式化合物反应以形成3式化合物，其中2式化合物的X为Cl或OH；(b) 用Lawesson试剂处理3式化合物以形成4式化合物；(c) 将4式化合物与氰化亚铁钾反应以生成5式化合物；(d) 用活性炭上的钯进行5式化合物的硝基团的催化还原，生成6式化合物，其中1-6式中的R1为H、C1-10烷基、C1-10烷氧基或C1-10卤代烷基，1-6式中的R2为H或C1-10烷基。本发明还提供了一种对患有至少一种肿瘤的患者进行光动力疗法的方法，包括以下步骤：向患者投药物学可接受的载体中的6式化合物（其中R1和R2如上所定义）；等待足够的时间以使给药的化合物被目标组织（至少一种肿瘤）吸收；照射患者身体含有目标组织的区域；从而抑制肿瘤的生长。
• Design, synthesis and antimetastatic evaluation of 1-benzothiazolylphenylbenzotriazoles for photodynamic therapy in oral cancer cells
  作者：Gopal Chandru Senadi、Chieh-Ming Liao、Kung-Kai Kuo、Jian-Cheng Lin、Long-Sen Chang、Jeh Jeng Wang、Wan-Ping Hu

  DOI：10.1039/c6md00034g

  日期：——

  We have designed and synthesized a new series of 1-benzothiazolylphenylbenzotriazoles 9a–p and studied their antimetastatic mechanism involved in photosensitive effects induced by UVA in oral cancer cell Ca9-22.

  我们设计并合成了一系列新的1-苯并噻唑基苯基三唑类化合物 9a–p 并研究了它们在口腔癌细胞Ca9-22中通过UVA诱导的光敏作用参与的抗转移机制。
• Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents
  作者：Wan-Ping Hu、Yin-Kai Chen、Chao-Cheng Liao、Hsin-Su Yu、Yi-Min Tsai、Shu-Mei Huang、Feng-Yuan Tsai、Ho-Chuan Shen、Long-Sen Chang、Jeh-Jeng Wang

  DOI：10.1016/j.bmc.2010.04.082

  日期：2010.8

  Photodynamic therapy (PDT) employing exogenous photosensitizers is currently being approved for treatment of basal cell carcinoma (BCC). 2-(4-Aminophenyl)benzothiazoles (6) consist of chromophoric structure and absorb light in the UVA (315–400 nm). These results encouraged us to design and synthesize a diversity of 2-phenylbenzothiazoles (6). Studies on the apoptotic mechanism involved in photosensitive effects

  使用外源光敏剂的光动力疗法（PDT）目前已被批准用于治疗基底细胞癌（BCC）。2-（4-氨基苯基）苯并噻唑（6）由发色结构组成，可吸收UVA（315-400 nm）中的光。这些结果鼓励我们设计和合成各种2-苯基苯并噻唑（6）。在本文中研究了UVC激活的6在BCC细胞中诱导的光敏效应所涉及的凋亡机制。用6 -UVA处理的细胞显示出一些凋亡特征，包括亚G1群体的增加，膜联蛋白V结合的显着增加以及caspase-3的激活。6-UVA诱导线粒体膜电位（Δ降低ψ公吨），并通过增强的ROS产生和胞外信号调节激酶（ERK）和p38 MAPK表达的促进磷酸ATP。这些结果表明6- UVA在涉及ERK和p38活化的线粒体过程中引起光敏作用，并最终导致BCC细胞凋亡。
• Synthesis and antiviral activity of sulfonamidobenzophenone oximes and sulfonamidobenzamides
  作者：Masaru Ogata、Hiroshi Matsumoto、Sumio Shimizu、Shiro Kida、Toru Wada、Motoo Shiro、Kosaburo Sato

  DOI：10.1021/jm00153a018

  日期：1986.3

  To find antiviral agents, various sulfonamidobenzophenone oximes (II) were synthesized from the appropriate m-sulfonamidobenzophenones by hydroxylamine reaction. The reaction products were generally obtained as syn/anti mixtures which were separable by fractional crystallization. The anti isomer had more potent antipoliovirus activity than the syn isomer. Various sulfonamidobenzamides (III) which were structurally related to II were synthesized by the reactions of amino-substituted benzamides with sulfuryl chloride or amines with (aminosulfonyl)benzoyl chloride. Antiviral activity was examined by the plaque-inhibition test. Compounds 5, 36, and 69 exhibited strong antipicornavirus activity. The structure-activity relationships are discussed.
• Cyclooxygenase-1-Selective Inhibitors Are Attractive Candidates for Analgesics That Do Not Cause Gastric Damage. Design and in Vitro/in Vivo Evaluation of a Benzamide-Type Cyclooxygenase-1 Selective Inhibitor
  作者：Hiroki Kakuta、Xiaoxia Zheng、Hiroyuki Oda、Shun Harada、Yukio Sugimoto、Kenji Sasaki、Akihiro Tai

  DOI：10.1021/jm701191z

  日期：2008.4.1

  Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4(trifluoromethyl)benzamide (18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1IC(50) = 0.80 +/- 0.05 mu M, COX-2IC(50) = 210 I mu M). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.